Author:
Li Xiaofei,Wang Fang,Jia Yizhen,Zhou He,Shi Yanting,Tian Feng,Chen Yan,Liang Jie
Abstract
AbstractThe pandemic of COVID-19 was a major public health events and had a deeply impact on the healthcare acquired by patients with inflammatory bowel disease (IBD). The purpose of this study was to evaluate the long-term impacts on healthcare service in Chinese IBD patients under the dynamic zero-COVID strategy. The study was performed in the Inflammatory Bowel Disease Quality of Care Centers in mainland China in 2021. The data about the healthcare was collected by a 44-item questionnaire. Totally 463 were from ulcerative colitis (UC) patients and 538 from Crohn’s disease (CD) patients were included in the study. The pandemic impacted 37.5% patients on their treatment, and the biggest problem was unable to follow up timely (77.9%). There was a significant increase in healthcare costs in CD (P < 0.001) and no significant change in UC (P = 0.14) after the outbreak. Both UC and CD had an increase in the frequency of outpatient visits (UC 5.07 vs. 4.54, P = 0.001; CD 6.30 vs. 5.76, P = 0.002), and hospitalizations (UC 1.30 vs. 1.02, P < 0.001; CD 3.55 vs. 2.78, P < 0.001). The hospitalization rate in UC reduced slightly (40.2% vs. 42.8%, P = 0.423) after the outbreak, but it significantly increased in CD (75.8% vs. 67.8%, P = 0.004). The rate of biologics had significant increased (UC 11.2% vs. 17.7%, P = 0.005; CD 53.2% vs. 71.0%, P < 0.001). Besides, the proportion of people using telemedicine also increased from 41.6% to 55.1% (P < 0.001). However, 82.8% patients still preferred face-to-face visits. Recurrent outbreaks and the regular pandemic prevention and control policy had a long-term impact on medical care service for IBD patients. The preferred mode of healthcare was still face-to-face visit. It will be a long way to go in the construction of telemedicine in China.
Funder
Natural Science Foundation of Shaanxi Province, Key Industrial Innovation Project Fund
National Natural Science Foundation of China Major Research Program Integration Project
School Science and Technology Development Fund of Air Force Military Medical University
Independent Funds of the Key Laboratory
Airforce Aoxiang Foundation
Young Changjiang Scholars of the Ministry of Education
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Wisniewski, A. et al. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United Eur. Gastroenterol. J. 8, 303–313. https://doi.org/10.1177/2050640619889763 (2020).
2. Garg, M. et al. Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: A novel therapeutic target?. Gut 69, 841–851. https://doi.org/10.1136/gutjnl-2019-318512 (2020).
3. Chen, Y. et al. Patterns of care for inflammatory bowel disease in China during the COVID-19 pandemic. Lancet Gastroenterol. Hepatol. 5, 632–634. https://doi.org/10.1016/S2468-1253(20)30131-X (2020).
4. Chen, J., Peng, X., Zhang, M. & Zhi, M. Impact of medication discontinuation on patients with inflammatory bowel disease during the COVID-19 outbreak. Gastroenterology 160, 2223. https://doi.org/10.1053/j.gastro.2020.05.087 (2021).
5. Inflammatory Bowel Disease Group of Chinese Society of Gastroenterology of Chinese Medical Association. Management of patients with inflammatory bowel disease during epidemic of 2019 novel coronavirus pneumonia. Chin. J. Dig. 40, E001 (2020).